TrialSignal
Clinical trial intelligence report
Utilization of Pulmonary Clearance Devices in Amyotrophic Lateral Sclerosis
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 13, 2026
NCT ID
NCT02682030
Status
COMPLETED
Phase
NA
Sponsor
Cedars-Sinai Medical Center
Executive brief
Investment-Ready Snapshot
The investigator is examining the use of one airway clearance medical device compared to the use of two airway clearance medical devices together in patients with amyotrophic lateral sclerosis (ALS). More specifically, the investigator wants to know how effective the use of either a mechanical High Frequency Chest Compression (HFCC) device is on its own or the use of both a mechanical High Frequency Chest Compression (HFCC) device and Cough Assist together to maintain a healthy airway and clear secretions. The first device is a passive form of mechanical High Frequency Chest Compression (HFCC), which was designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area. The second device, called a Cough Assist, aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing. This study will enroll up to 20 people in total at CSMC.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT02682030
Indication
Amyotrophic Lateral Sclerosis
Modality
medical device
Target
High Frequency Chest Compression Device (HFCC), Cough Assist
Intervention
High Frequency Chest Compression Device (HFCC), Cough Assist
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.